Life sciences & health care M&A update: Q3 2018
The life sciences and health care industry has historically faced challenges when it comes to drug development and its complex processes. Master Protocol, a new streamlined and time-effective process may be a solution to help address the slow drug development process. This life sciences and health care mergers and acquisitions (M&A) update provides Deloitte Corporate Finance LLC insights and market data analysis that shed light on M&A trends in the life sciences and health care industry.
Challenges facing drug development
As biopharma companies face challenges regarding the slow process of drug development, many have begun to implement the process known as Master Protocol, in-order-to answer multiple questions within a drug development phase in a shorter amount of time.1
Potential benefits of Master Protocols2
- Streamlines logistics: Multiple stakeholders can come together to collect, synthesize, and analyze various treatment combinations and effects of competing drugs.
- Reduces cost and cycle time: Reduces pharma companies’ time to activation, which helps alleviate the cost barrier facing the current model of drug development.
- Continuous learning: Successful collaborative groups can work together to share knowledge about the effectiveness of a certain therapy, or a certain group of therapies, on a specific disease.
This newsletter is a periodic compilation of certain capital markets information.
1 Deloitte Center for Health Solutions (DCHS). Master Protocol Clinical Trial Drug Development Process. October 2018.